DARA BioSciences, Inc
. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, is sponsoring a breast cancer patient
education segment on The Balancing Act®
airing on Lifetime Television. The segment, which airs Oct. 14 and 21 at 7 a.m. EDT during Breast Cancer Awareness Month, features Nancy Peacock, MD, Tennessee Oncology medical oncologist and breast cancer specialist at St. Thomas Midtown Hospital in Nashville, Tenn., and breast cancer survivor Julie Megee of Wrentham, Mass.
Nancy Peacock, MD, and breast cancer survivor, Julie Megee from Wrentham, Mass., join The Balancing Act(R) host Danielle Knox in studio and discuss important oncology supportive care issues (Photo: Business Wire)
Dr. Peacock and Ms. Megee join The Balancing Act
host Danielle Knox in studio and discuss important oncology supportive care issues, including patient compliance to tamoxifen, and how
(tamoxifen citrate) oral solution may help benefit compliance. The segment also touches on side effects of cancer treatment, including skin burns and oral mucositis caused by radiation treatment and chemotherapy. DARA markets
, an oral rinse gel for relief of oral mucositis pain, and
, a topical treatment for skin irritation and burns, in the US oncology/radiology markets. Dr. Peacock and Julie also discuss the important role of patient educational resources such as
“We are pleased to partner with The Balancing Act
to produce this educational segment about breast cancer treatment and support, and appreciate The Balancing Act’s commitment to breast cancer education and programming during Breast Cancer Awareness Month,” said
David J. Drutz, MD
, DARA's chief executive officer and chief medical officer. “We are grateful to Dr. Peacock and Ms. Megee for sharing their experiences on national television, so that others may learn from their insights and knowledge.”
One issue that ties Dr. Peacock and Ms. Megee together is tamoxifen therapy. According to recently published National Comprehensive Cancer Network (NCCN) Guidelines (Version 3.2013), tamoxifen is the most firmly established adjuvant endocrine therapy for both premenopausal and postmenopausal women with estrogen receptor-positive breast cancer. Tamoxifen is usually administered as 20mg daily for five years. The American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines published on July 8, 2013, recommends that in women at increased risk of breast cancer age 35 or older, tamoxifen prophylaxis (20mg per day for five years) should be discussed as an option to reduce the risk of estrogen receptor (ER) positive breast cancer. Soltamox
(tamoxifen citrate) oral solution is bioequivalent to tamoxifen and is prescribed for the same indications. Please see Soltamox Important Safety Information and the Black Box Warning at the end of this press release. For additional information and a copy of the complete Prescribing Information visit
Megee, a 41-year-old mother of two and owner of
Perceptions Hair Studio
in Norton, Mass., asked her physician about the option of using Soltamox
instead of tamoxifen tablets because of her long-standing aversion to pills. Dr. Peacock recommends physicians discuss the importance of adherence to tamoxifen/Soltamox
therapy in detail because many patients do not realize its significance in preventing the recurrence of breast cancer. Studies show between 30 and 70 percent of patients who are prescribed tamoxifen as adjuvant therapy fail to complete their prescribed course of treatment which can increase the risk of breast cancer recurrence.
Education and support from family, friends and other women who have battled breast cancer play key roles in patients’ lives, said both Dr. Peacock and Ms. Megee. Both discuss the value and importance of online educational resources and communities like Breastcancer.org.